Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia. It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).